Cancer Mutation Profiling and Interpretation
| Label Mnemonic: | CMPBM |
| Epic code: | LAB8094 |
| Downtime form: | A-1a Doctor/Provider Orders - Pathology Molecular |
Molecular Pathology
6240 RCP
384-9568
6240 RCP
384-9568
Specimen(s):
Bone Marrow Aspirate
Specimen
Instructions:
Specimen requires 20% or greater tumor cell content. Please provide the FFPE block or 10 unstained 5-10 μM slides with an H&E slide of the tissue.
Testing requires dedicated collection tube.
Testing requires dedicated collection tube.
Collection Medium:
 |
| Pink top tube 6 mL (K2-EDTA) |
Minimum:
2 mL Bone Marrow Aspirate in EDTA (pink tube).
Rejection Criteria:
Specimens fixed in B5 fixative or decalcified will not be accepted.
Tumor specimens containing less than 20% tumor cells may be
unacceptable.
Testing Schedule:
Weekly
Turn Around
Time:
21 days
Comments:
The Cancer Mutation Profiling test is a massively parallel next
generation DNA sequencing-based assay that targets commonly mutated
or hotspot regions of 50 cancer-related genes.
Genes Assessed: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARC1, SMO, SRC, STK11, TP53, and VHL.
Genes Assessed: ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARC1, SMO, SRC, STK11, TP53, and VHL.
Methodology:
Massively parallel Next Generation DNA sequencing by synthesis,
semiconductor technology, Ion Torrent
CPT Code:
81445